Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

  • Vázquez-Castellanos, J. F.
  • Serrano-Villar, S.
  • Latorre, A.
  • Artacho, A.
  • Ferrús, M. L.
  • Madrid, N.
  • Vallejo, Alejandro
  • Sainz, T.
  • Martínez-Botas, J.
  • Ferrando-Martínez, Sara
  • Vera, Mar
  • Dronda, Fernando
  • Leal, Mauel
  • Romero, Jorge del
  • Moreno, Santiago
  • Estrada Pérez, Vicente
  • Gosalbes, M. J.
  • Moya, A.
Altered interplay between gut mucosa and microbiota during treated HIV infection may possibly contribute to increased bacterial translocation and chronic immune activation, both of which are predictors of morbidity and mortality. Although a dysbiotic gut microbiota has recently been reported in HIV+ individuals, the metagenome gene pool associated with HIV infection remains unknown. The aim of this study is to characterize the functional gene content of gut microbiota in HIV+ patients and to define the metabolic pathways of this bacterial community, which is potentially associated with immune dysfunction. We determined systemic markers of innate and adaptive immunity in a cohort of HIV-infected individuals on successful antiretroviral therapy without comorbidities and in healthy non-HIV-infected subjects. Metagenome sequencing revealed an altered functional profile, with enrichment of the genes involved in various pathogenic processes, lipopolysaccharide biosynthesis, bacterial translocation, and other inflammatory pathways. In contrast, we observed depletion of genes involved in amino acid metabolism and energy processes. Bayesian networks showed significant interactions between the bacterial community, their altered metabolic pathways, and systemic markers of immune dysfunction. This study reveals altered metabolic activity of microbiota and provides novel insight into the potential host–microbiota interactions driving the sustained inflammatory state in successfully treated HIV-infected patients., This work was supported by “Generalitat Valenciana” (Prometeo/2009/092) and by the Spanish Ministry of Economy and Competitiveness (SAF2012-31187), Redes Temáticas de Investigación en SIDA (ISCIII RETIC RD12/0017/0029 and RD12/0017/0037), and Junta de Andalucia (Proyecto de Excelencia CTS-6313). J.F.V.C. was supported by a fellowship “Ayudas Predoctorales de Formación en Investigación en Salud” from the Instituto de Salud Carlos III, Spain. S.S.V. and T.S. were supported by a grant from the Spanish Ministry of Science and Innovation (Ayudas para Contratos de Formación en Investigación Río Hortega). S.F.M. holds a grant from the Fondo de Investigaciones Sanitarias (CD10/00382)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

  • Crichton, S.
  • Belfrage, E.
  • Collins, I.J.
  • Doerholt, K.
  • Judd, A.
  • Le Coeur, S.
  • Spoulou, V.
  • Goodall, R.
  • Scherpbier, H.
  • Smit, C.
  • Goetghebuer, T.
  • Gibb, D.M.
  • Noguera, A.
  • Navarro, M.L.
  • Ramos, J.T.
  • Galli, L.
  • Giaquinto, C.
  • Thorne, C.
  • Santa Ansone.
  • Marczynska, M.
  • Okhonskaia, L.
  • de Tejada, BM.
  • Jourdain, G.
  • Decker, L.
  • Ene, L.
  • Hainaut, M.
  • Van der Kelen, E.
  • Delforge, M.
  • de Martino, M.
  • Tovo, PA.
  • Patrizia, O.
  • Larovere, D.
  • Ruggeri, M.
  • Faldella, G.
  • Baldi, F.
  • Badolato, R.
  • Montagnani, C.
  • Venturini, E.
  • Lisi, C.
  • Di Biagio, A.
  • Taramasso, L.
  • Giacomet, V.
  • Erba, P.
  • Esposito, S.
  • Lipreri, R.
  • Salvini, F.
  • Tagliabue, C.
  • Cellini, M.
  • Bruzzese, E.
  • Lo Vecchio, A.
  • Rampon, O.
  • Dona, D.
  • Romano, A.
  • Dodi, I.
  • Maccabruni, A.
  • Consolini, R.
  • Bernardi, S.
  • Kuekou, HT.
  • Genovese, O.
  • Olmeo, P.
  • Cristiano, L.
  • Mazza, A.
  • Gabiano, C.
  • Garazzino, S.
  • Pellegatta, A.
  • Pajkrt, D.
  • Scherpbier, HJ.
  • Weijsenfeld, AM.
  • de Boer, CG.
  • Jurriaans, S.
  • Back, NKT.
  • Zaaijer, HL.
  • Berkhout, B.
  • Cornelissen, MTE.
  • Schinkel, CJ.
  • Wolthers, KC.
  • Fraaij, PLA.
  • van Rossum, AMC.
  • Vermont, CL.
  • van der Knaap, LC.
  • Visser, EG.
  • Boucher, CAB.
  • Koopmans, MPG.
  • van Kampen, JJA.
  • Pas, SD.
  • Henriet, SSV.
  • van de Flier, M.
  • van Aerde, K.
  • Strik-Albers, R.
  • Rahamat-Langendoen, J.
  • Stelma, FF.
  • Scholvinck, EH.
  • de Groot-de Jonge, H.
  • Niesters, HGM.
  • van Leer-Buter, CC.
  • Knoester, M.
  • Bont, LJ.
  • Geelen, SPM.
  • Wolfs, TFW.
  • Nauta, N.
  • Schuurman, R.
  • Verduyn-Lunel, F.
  • Wensing, AMJ.
  • Reiss, P.
  • Zaheri, S.
  • Bezemer, DO.
  • van Sighem, AI.
  • Smit, C.
  • Wit, FWMN.
  • Hillebregt, M.
  • de Jong, A.
  • Woudstra, T.
  • Bergsma, D.
  • Grivell, S.
  • Meijering, R.
  • Raethke, M.
  • Rutkens, T.
  • de Groot, L.
  • van den Akker, M.
  • Bakker, Y.
  • Bezemer, M.
  • El Berkaoui, A.
  • Geerlinks, J.
  • Koops, J.
  • Kruijne, E.
  • Lodewijk, C.
  • Lucas, E.
  • van der Meer, R.
  • Munjishvili, L.
  • Paling, E.
  • Peeck, B.
  • Ree, C.
  • Regtop, R.
  • Ruijs, Y.
  • van de Sande, L.
  • Schoorl, M.
  • Schnorr, P.
  • Tuijn, E.
  • Veenenberg, L.
  • van der Vliet, S.
  • Wisse, A.
  • Witte, EC.
  • Tuk, B.
  • Popielska, J.
  • Pokorska-Spiewak, M.
  • Oldakowska, A.
  • Zawadka, K.
  • Coupland, U.
  • Doroba, M.
  • Voronin, E.
  • Miloenko, M.
  • Labutina, S.
  • Soler-Palacin, P.
  • Frick, MA.
  • Perez-Hoyos, S.
  • Mur, A.
  • Lopez, N.
  • Mendez, M.
  • Mayol, L.
  • Vallmanya, T.
  • Calavia, O.
  • Garcia, L.
  • Coll, M.
  • Pineda, V.
  • Rius, N.
  • Rovira, N.
  • Duenas, J.
  • Gamell, A.
  • Fortuny, C.
  • Noguera-Julian, A.
  • Mellado, MJ.
  • Escosa, L.
  • Hortelano, MG.
  • Sainz, T.
  • Gonzalez-Tome, MI.
  • Rojo, P.
  • Blazquez, D.
  • Prieto, L.
  • Guillen, S.
  • Saavedra, J.
  • Santos, M.
  • Munoz, MA.
  • Ruiz, B.
  • Mc Phee, CF.
  • de Ory, SJ.
  • Alvarez, S.
  • Roa, MA.
  • Beceiro, J.
  • Martinez, J.
  • Badillo, K.
  • Apilanez, M.
  • Pocheville, I.
  • Garrote, E.
  • Colino, E.
  • Sirvent, JG.
  • Garzon, M.
  • Roman, V.
  • Montesdeoca, A.
  • Mateo, M.
  • Munoz, MJ.
  • Angulo, R.
  • Neth, O.
  • Falcon, L.
  • Terol, P.
  • Santos, JL.
  • Moreno, D.
  • Lendinez, F.
  • Grande, A.
  • Romero, FJ.
  • Perez, C.
  • Lillo, M.
  • Losada, B.
  • Herranz, M.
  • Bustillo, M.
  • Guerrero, C.
  • Collado, P.
  • Couceiro, JA.
  • Perez, A.
Objective: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. Methods: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. Results: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean. Conclusion: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART

  • Gómez, Carmen Elena
  • Perdiguero, Beatriz
  • García-Arriaza, Juan
  • Cepeda, Victoria
  • Sánchez-Sorzano, Carlos Óscar
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Jímenez, Jose Luis
  • Muñoz Fernández, María Ángeles
  • Gatell, José Mª|||0000-0002-4705-3244
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • Brander, Christian|||0000-0002-0548-5778
  • García, Felipe|||0000-0001-7658-5832
  • Esteban, Mariano|||0000-0003-0846-2827
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo,followed by interruption of HAART. METHODS: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. RESULTS: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. CONCLUSION: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. TRIAL REGISTRATION: ClinicalTrials. gov NCT01571466.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients

  • Falcon-Neyra, Lola
  • Palladino, Claudia
  • Navarro, Maria Luisa
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • González-Tomé, María Isabel
  • De Ory, Santiago J.
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Fortuny Guasch, Claudia
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Bermúdez Moreno, Elena
  • Santos, Juan Luis
  • Olbrich, Peter
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Briz, Verónica|||0000-0003-2297-5098
  • Neth, Olaf|||0000-0001-5018-0466
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez De Ory, S.
  • Ramos Amador, José Tomás
  • Fortuny Guasch, Claudia
  • González-Tomé, María Isabel
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Moreno Pérez, David|||0000-0002-7017-4095
  • Gavilán, C.
  • Menasalvas, A. I.
  • Piqueras, Ana Isabel
  • Frick, Marie Antoinette|||0000-0002-2553-5090
  • Muñoz-Fernández, M. A.
  • Navarro, Maria Luisa
Background There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013

  • Jiménez de Ory, Santiago
  • González-Tomé, María Isabel
  • Fortuny Guasch, Claudia
  • Mellado Peña, María José|||0000-0003-2251-9666
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Bustillo, Matilde
  • Ramos Amador, José Tomás
  • Muñoz-Fernández, Maria Angeles
  • Navarro, Maria Luisa
Vertical human immunodeficiency virus (HIV) infection has decreased in industrialized countries in recent decades, but there are no studies on the mechanisms of HIV transmission among infected children in Spain. Our aim was to study the characteristics and trends of diagnoses of vertically HIV-infected children in Spain from 2004 to 2013. Vertically HIV-infected children were selected if they were diagnosed from 2004 to 2013, were aged 0 to 18 years old, and were included in the Cohort of the Spanish Pediatric HIV Network (CoRISpe). Demographic, clinical, immunological, and virological data at diagnosis were obtained. The rate of diagnoses of vertically HIV-infected children was calculated as the number of cases per 100,000 inhabitants. Obstetric data of mothers of Spanish children and prophylaxis at childbirth and postpartum were obtained. A total of 218 HIV-infected children were included in the study. Of this sample, 182 children (83.5%) were perinatally HIV infected, and 125 out of those 182 children (68.7%) were born in Spain. The vertically HIV-infected Spanish children were diagnosed earlier and were in better clinical and immunological condition at diagnosis than were foreign children. The rate of vertically HIV-infected children declined from 0.09 in 2004 to 0.03 in 2013 due to the decrease in the rate of children born in Spain (0.08 in 2004 vs 0.01 in 2013). A total of 60 out of 107 mothers (56.1%) of Spanish children were diagnosed at or after childbirth. However, this number declined between 2004 and 2013. The rate of new HIV diagnoses of vertically HIV-infected children decreased significantly between 2004 and 2013 from 0.09 to 0.03 per 100,000 inhabitants.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

  • Jiménez de Ory, Santiago
  • Ramos, José Tomas
  • Fortuny, Clàudia
  • González-Tomé, María Isabel
  • Mellado, Maria José
  • Moreno, David
  • Frick, Marie Antoinette
Retrospective study; Spanish Paediatric HIV Network; Rates of perinatal HIV, Estudio retrospectivo; Red Española de VIH Pediátrico; Tasas de VIH perinatal, Estudi retrospectiu; Xarxa espanyola de VIH Pediàtrica; Taxes de VIH perinatal, Background: There are not enough nationwide studies on perinatal HIV transmission in connection with a combination of antiretroviral treatments in Spain. Our objectives were to study sociodemographic changes and trends in the rates of HIV diagnoses and perinatal transmission in Spain from 1997 to 2015. Methods: A retrospective study using data from Spanish Paediatric HIV Network (CoRISpe) and Spanish Minimum Basic Data Set (MDBS) was performed. HIV- diagnosed children between 1997 and 2015 were selected. Sociodemographic, clinical and immunovirological data of HIV-infected children and their mothers were studied in four calendar periods (P1: 1997-2000; P2: 2001-2005; P3: 2006-2010; P4: 2011-2015). Rates of perinatal HIV diagnoses and transmission from 1997 to 2015 were calculated. Results: A total of 532 HIV-infected children were included in this study. Of these children, 406 were Spanish (76.3%) and 126 immigrants (23.7%). A decrease in the number of HIV diagnoses, 203 (38.2%) children in the first (P1), 149 (28%) in the second (P2), 130 (24.4%) in the third (P3) and 50 (9.4%) in the fourth (P4) calendar periods was studied. The same decrease in the Spanish HIV-infected children (P1, 174 (46.6%), P2, 115 (30.8%), P3, 65 (17.4%) and P4, 19 (5.1%)) was monitored. However, an increase in the number of HIV diagnoses by sexual contact (P1: 0%; P2: 1.3%; P3: 4.6%; P4: 16%) was observed. The rates of new perinatal HIV diagnoses and perinatal transmission in Spanish children decreased from 0.167 to 0.005 per 100,000 inhabitants and 11.4% to 0.4% between 1997 and 2015, respectively. Conclusions: A decline of perinatal HIV diagnoses and transmission was observed. However, an increase of teen-agers HIV diagnoses with sexual infection was studied. Public awareness campaigns directed to teen-agers are advisable to prevent HIV infection by sexual contact., This work has been partially funded by Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035, RD12/0017/0037 and RD16/0025/0019), project as part of the Plan R+D+I (2008-2011; 2013-2016) and cofinanced by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER), RISEPICLIN-19/2015, Fondo para la Investigación Sanitaria of the Spanish Ministry of Science and Innovation (FIS PI13/00422, PI16/01863), CYTED (214RT0482) and EPIICAL Project. CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, the Consolider Program, and CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. COST CA17140 Cancer Nanomedicine-Front The Bench to Bebside. We thank the Spanish HIV HGM BioBank supported by ISC III project RETIC PT13/0010/0028 and PT17/0015/0042. No funding for this work was received from National Institutes of Health (NIH), Wellcome Trust and Howard Hughes Medical Institute (HHMI)